Inhibition of P-glycoprotein by newer antidepressants

Journal of Pharmacology and Experimental Therapeutics

Volumn 305, Issue 1, 2003, Pages 197-204

  Weiss, Johanna ^a   Dormann, Sven Maria Gregor ^a   Martin Facklam, Meret ^a   Kerpen, Christian Johannes ^a   Ketabi Kiyanvash, Nahal ^a   Haefeli, Walter Emil ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CALCEIN; CITALOPRAM; DESVENLAFAXINE; DRUG METABOLITE; FLUOXETINE; FLUVOXAMINE; GLYCOPROTEIN P; N NORVENLAFAXINE; NORCITALOPRAM; NORFLUOXETINE; NORSERTRALINE; PAROXETINE; PAROXETINE M; QUINIDINE; REBOXETINE; SERTRALINE; UNCLASSIFIED DRUG; VALSPODAR; VENLAFAXINE; VERAPAMIL; ZOSUQUIDAR;

ANIMAL CELL; ARTICLE; BIOASSAY; BLOOD BRAIN BARRIER; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SWINE;

ANIMALS; ANTIDEPRESSIVE AGENTS; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; HUMANS; P-GLYCOPROTEIN; REPRODUCIBILITY OF RESULTS; SWINE; TRANSFECTION;

EID: 0037379938     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.046532     Document Type: Article

References (40)

1. Audus KL, Ng L, Wang W, and Borchardt RT (1996) Brain microvessel endothelial cell culture systems. Pharm Biotechnol 8:239-258.
2. Bogman K, Peyer AK, Török M, Kusters E, and Drewe J (2001) HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol 132:1183-1192.
3. Bollini P, Pampallona S, Tibaldi G, Kupelnick B, and Munizza C (1999) Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials. Br J Psychiatry 174:297-303.
4. Caccia S (1998) Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet 34:281-302.
5. Childs S and Ling V (1996) Duplication and evolution of the P-glycoprotein genes in pig. Biochim Biophys Acta 1307:205-212.
6. Chiou WL, Chung SM, and Wu TC (2000) Potential role of P-glycoprotein in affecting hepatic metabolism of drugs. Pharm Res 17:903-905.
7. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, and Bertino JR (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86:695-698.
8. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, et al. (2002) Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol 61:964-973.
9. Eneroth A, Astrom E, Hoogstraate J, Schrenk D, Conrad S, Kauffmann HM, and Gjellan K (2001) Evaluation of a vincristine resistant Caco-2 cell line for use in a calcein AM extrusion screening assay for P-glycoprotein interaction. Eur J Pharm Sci 12:205-214.
10. Feller N, Broxterman HJ, Wahrer DC, and Pinedo HM (1995) ATP-dependent efflux of calcein by the multidrug resistance protein (MRP): no inhibition by intracellular glutathione depletion. FEBS Lett 368:385-388.
11. Gollapudi S, Kim CH, Tran BN, Sangha S, and Gupta S (1997) Probenecid reverses multidrug resistance in multidrug resistance-associated protein-overexpressing HL60/AR and H69/AR cells but not in P-glycoprotein-overexpressing HL60/Tax and P388/ADR cells. Cancer Chemother Pharmacol 40:150-158.
12. Hegmann EJ, Bauer HC, and Kerbel RS (1992) Expression and functional activity of P-glycoprotein in cultured cerebral capillary endothelial cells. Cancer Res 52: 6969-6975.
13. Hollo Z, Homolya L, Hegedus T, and Sarkadi B (1996) Transport properties of the multidrug resistance-associated protein (MRP) in human tumour cells. FEBS Lett 383:99-104.
14. Homolya L, Hollo Z, Germann UA, Pastan I, Gottesman MM, and Sarkadi B (1993) Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem 268:21493-21496.
15. Huwyler J, Drewe J, Klusemann C, and Fricker G (1996) Evidence for P-glycoprotein-modulated penetration of morphine-6-glucuronide into brain capillary endothelium. Br J Pharmacol 118:1879-1885.
16. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, and Wilkinson GR (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289-294.
17. Kusuhara H, Suzuki H, and Sugiyama Y (1998) The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs. J Pharm Sci 87:1025-1040.
18. Larsen F, Priskorn M, and Overo KF (2001) Lack of citalopram effect on oral digoxin pharmacokinetics. J Clin Pharmacol 41:340-346.
19. Leibovitz A, Bilchinsky T, Gil I, and Habot B (1998) Elevated serum digoxin level associated with coadministered fluoxetine. Arch Intern Med 158:1152-1153.
20. Ochs HR, Greenblatt DJ, Verburg-Ochs B, and Labedski L (1989) Chronic treatment with fluvoxamine, clovoxamine and placebo: interaction with digoxin and effects on sleep and alertness. J Clin Pharmacol 29:91-95.
21. Preskorn SH (1996) Clinical Pharmacology of Selective Serotonin Reuptake Inhibitors, Professional Communications, Caddo.
22. Preskorn SH (1997) Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 32 (Suppl 1):1-21.
23. Rameis H (1985) Quinidine-digoxin interaction: are the pharmacokinetics of both drugs altered? Int J Clin Pharmacol Ther Toxicol 23:145-153.
24. Rapeport WG, Coates PE, Dewland PM, and Forster PL (1996) Absence of a sertraline-mediated effect on digoxin pharmacokinetics and electrocardiographic findings. J Clin Psychiatry 57 (Suppl 1):16-19.
25. Rochat B, Baumann P, and Audus KL (1999) Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium. Brain Res 831:229-236.
26. Sadeque AJ, Wandel C, He H, Shah S, and Wood AJ (2000) Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 68:231-237.
27. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP, et al. (1994) Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502.
28. Schinkel AH, Wagenaar E, Mol CA, and van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517-2524.
29. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, and Borst P (1995) Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporin A. J Clin Invest 96:1698-1705.
30. Sindrup SH, Brosen K, and Gram LF (1992) Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 51:288-295.
31. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P, Nooijen WJ, Beijnen JH, and van Tellingen O (1997) Limited oral bioavailability and active epithelial excretion ofpaclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031-2035.
32. Stockley IH (1999) Drug Interactions, A Source Book of Adverse Interactions, Their Mechanisms, Clinical Importance and Management. Pharmaceutical Press, London.
33. Tiberghien F and Loor F (1996) Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anticancer Drugs 7:568-578.
34. Török M, Gutmann H, Fricker G, and Drewe J (1999) Sister of P-glycoprotein expression in different tissues. Biochem Pharmacol 57:833-835.
35. Uhr M (2002) Einfluss des P-Glykoproteins auf die Blut-Hirn-Schrankenfunktion. Ph.D. thesis, University of Bielefeld, Bielefeld, Germany.
36. Uhr M, Steckler T, Yassouridis A, and Holsboer F (2000) Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 22:380-387.
37. van Asperen J, Mayer U, van Tellingen O, and Beijnen JH (1997) The functional role of P-glycoprotein in the blood-brain barrier. J Pharm Sci 86:881-884.
38. van Asperen J, van Tellingen O, and Beijnen JH (1998) The pharmacological role of P-glycoprotein in the intestinal epithelium. Pharmacol Res 37:429-435.
39. von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, and Shader RI (1998) In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol 55:113-122.
40. Yu DK (1999) The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J Clin Pharmacol 39:1203-1211.